2 income funds that have thrashed Neil Woodford

These two benchmark-thrashing equity income fund managers have given Neil Woodford a run for his money, says Harvey Jones.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Everybody loves star fund manager Neil Woodford, or rather they did. One year of underperformance and the doubters are out in force. CF Woodford Equity Income hasn’t done as badly as people claim, rising 13.1% in the past 12 months, but it still trailed its benchmark equity income index which grew 16.1%, and people don’t expect that. So should you shun the blue-eyed boy of equity income?

Stormy weather

Woodford has been through rough waters before, as you would expect with a manager who is happy to swim against the tide, and has always emerged with his reputation enhanced. I expect him to do it again, but it is always worth checking out the competition. Different fund managers have different styles and invest in different stocks, giving you much-needed diversification. The following two have outpaced Woodford over the last year, although they may not always do so.

Ben Whitmore’s £2.3bn Jupiter Income Trust is a minnow next to Woodford’s £10bn giant. But small is beautiful with the fund returning 23% in the past year, and 75% over five years. It has some crossover with the Woodford vehicle, both feature pharmaceutical stocks AstraZeneca and GlaxoSmithKline, although these two make up a whopping 16.48% of Woodford’s total fund, more than double Jupiter’s 7.7% exposure. Woodford has also gone massive on tobacco stocks, with a 14.21% total weighing in Imperial Brands and British American Tobacco, far greater than Jupiter.

Going global

These are Woodford’s hits. His misses include ignoring oil and commodity stocks, which enjoyed a bumper 2016, and going big on outsourcing company Capita Group, whose share price halved. He also shunned the banks while Whitmore has a 4.8% stake in HSBC Holdings, which leapt 50% in the last year.

Jupiter Income is 100% invested in the UK, Woodford Equity Income is around 14% exposure to other countries, notably the US, with smaller stakes in Norway, Ireland, Luxembourg and Switzerland. Robin Geffen’s Neptune Income has even greater US exposure at 20%, and its top 10 holdings feature no less than five US stocks: Microsoft Corporation, derivatives marketplace CME Group, JP Morgan Chase & Co, Wells Fargo & Co and Johnson Matthey.

Sector splits

Neptune Income therefore gives you greater diversification, with a completely different top 10 to Woodford. It also has has more energy exposure with a 3.34% stake in Royal Dutch Shell, and 3.26% in Rio Tinto. Geffen has returned 20% over the past year, and 55% over five years. 

Drilling down further, Woodford has 36.85% exposure to healthcare and 28.33% in financials, but has next to nothing in technology, consumer services, utilities or telecommunications. Jupiter Income has 25% in financials and 20% in consumer services, but then has a much more even spread of sectors. It is a similar story with Neptune, which has major financials exposure at 34%, followed by a broad spread across the sectors. You can see which man is making the big calls here: Woodford. Next year those calls might pay off.

Three-way bet

Finally, the income. Neptune is the high highest yielding of the three, returning 4.66% a year, beating Jupiter’s 3.5% and Woodford’s 3.17%. So a spread of all three funds may give you better balance than going all-in on Woodford.

Harvey Jones holds units in CF Woodford Equity Income but has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca, BP, HSBC Holdings, Imperial Brands, Rio Tinto, and Royal Dutch Shell B. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The key number that could signal a recovery for the Greggs share price in 2026

The Greggs share price has crashed in 2025, but is the company facing serious long-term challenges or are its issues…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Can the Rolls-Royce share price hit £16 in 2026? Here’s what the experts think

The Rolls-Royce share price has been unstoppable. Can AI data centres and higher defence spending keep the momentum going in…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

Up 150% in 5 years! What’s going on with the Lloyds share price?

The Lloyds share price has had a strong five years. Our writer sees reasons to think it could go even…

Read more »

Investing Articles

Where will Rolls-Royce shares go in 2026? Here’s what the experts say!

Rolls-Royce shares delivered a tremendous return for investors in 2025. Analysts expect next year to be positive, but slower.

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Up 40% this year, can the Vodafone share price keep going?

Vodafone shareholders have been rewarded this year with a dividend increase on top of share price growth. Our writer weighs…

Read more »

Buffett at the BRK AGM
Investing Articles

Here’s why I like Tesco shares, but won’t be buying any!

Drawing inspiration from famed investor Warren Buffett's approach, our writer explains why Tesco shares aren't on his shopping list.

Read more »

Investing For Beginners

If the HSBC share price can clear these hurdles, it could fly in 2026

After a fantastic year, Jon Smith points out some of the potential road bumps for the HSBC share price, including…

Read more »

Investing Articles

I’m thrilled I bought Rolls-Royce shares in 2023. Will I buy more in 2026?

Rolls-Royce has become a superior company, with rising profits, buybacks, and shares now paying a dividend. So is the FTSE…

Read more »